STAT

DECEMBER 28, 2023

Health insurance giant UnitedHealth Group used secret rules to restrict access to rehabilitation care requested by specific groups of seriously ill patients, including those who lived in nursing homes or suffered from cognitive impairment, according to internal documents obtained by STAT. The documents, which outline parameters for the clinicians who initially review referrals for rehab care, reveal that many patients enrolled in Medicare Advantage plans were routed for a quick denial based on c

Nursing Homes 363

Nursing Homes Documentation 363

The Script

DECEMBER 28, 2023

Balancing workloads and quality patient care is challenging in the pharmaceutical industry. Learn how to perfect your ratios from Rx relief.

Pharmacy Management 105

Pharmacy Management 105

STAT

DECEMBER 28, 2023

A slate of liver diseases got a rebrand this year. Experts hope the change can generate more conversation — and research interest — for conditions that still lack treatments.  A group of over 200 physicians, public health experts, industry representatives, regulatory officials, and patient advocates made the call in a supermajority vote: Non-alcoholic fatty liver disease, or NAFLD, would be renamed metabolic dysfunction-associated steatotic liver disease.

305

305

Express Pharma

DECEMBER 28, 2023

Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by GlobalData. The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18 per cent) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year.

Drug Development 92

Drug Development 92

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 28, 2023

There’s an old story in journalism, and it goes like this: A reporter is asked, “What’s the best story you’ve ever written?” The reply? “The one I’m doing for tomorrow.” There’s a lot of that at STAT, and that’s why we’ve assembled an in-case-you-missed-it list of great stories from this year.

Hospitals 244

Hospitals 244

Express Pharma

DECEMBER 28, 2023

In November 2023, the Indian Union Health Ministry authorised the sale of four generic medications for the treatment of rare diseases. This approval is a significant milestone in the fight against rare diseases in India. These approved indigenous products, along with other products yet to be approved, will aid patients suffering from rare diseases. However, a major obstacle to effectively combating rare diseases in India is the lack of awareness and inadequate diagnosis in the country, says Glob

Diabetes 88

Diabetes 88

Pharmaceutical Technology

DECEMBER 28, 2023

J&J has acquired a global license for South Korean LegoChem’s ADC for $100m upfront along with milestone-based payments and tiered royalties.

98

98

STAT

DECEMBER 28, 2023

For most states, the new year means a new legislative session. STAT’s taking a look at some of the recent health policy trends that states will start to implement in 2024. As health care expenditures continue to grow nationally, states are especially interested in increasing how much oversight they have over health care costs — not just for their state Medicaid programs, but also for private insurance.

Drug Pricing 238

Drug Pricing Hospitals 238

EMCrit Project

DECEMBER 28, 2023

Setting PEEP and Righting the RV in ARDS with Matt Siuba EMCrit Project by Scott Weingart, MD FCCM.

116

116

European Pharmaceutical Review

DECEMBER 28, 2023

In this exclusive interview, Andreas Harstrick, the Chief Medical Officer of Affimed unveils the potential of innate cell engagers for treating lymphoma. As well as presenting recent findings from the pivotal AFM13-104 study, Andreas also reflects on the challenges encountered and conquered in developing Affimed’s innate cell engager, Acimtamig, which targets CD30 on lymphoma cells and CD16A on NK cells.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmaceutical Technology

DECEMBER 28, 2023

The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.

98

98

World Pharma News

DECEMBER 28, 2023

Brigham researchers' findings from next-generation sequencing suggest that revising current cancer care guidelines could allow approximately 6,000 more patients in the U.S. to benefit from immunotherapy treatment each year. Immunotherapy is a highly effective treatment for patients whose cancers harbor mismatch repair deficiency, and a new study identifies more cancer patients who could benefit from this form of therapy.

80

80

pharmaphorum

DECEMBER 28, 2023

Cytokinetics rises on report that its aficamten drug improved symptoms in people with rare disease obstructive hypertrophic cardiomyopathy

85

85

Big Molecule Watch

DECEMBER 28, 2023

As previously reported by Big Molecule Watch, trial in Regeneron’s BPCIA case against Biocon regarding Biocon’s proposed aflibercept biosimilar concluded on June 15, 2023 in the Northern District of West Virginia. The patents-at-issue are directed to formulations and dosing regimens for aflibercept, an anti-VEGF treatment for retinal disorders including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Biosimilars 67

Biosimilars Diabetes 67

pharmaphorum

DECEMBER 28, 2023

In this third instalment of the five-part, festive series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Mark Andrews, investment director of life sciences funds at British Patient Capital (BPC), discussing the vitally hot topic of investment in life sciences.

62

62

Drug Patent Watch

DECEMBER 28, 2023

Annual Drug Patent Expirations for NOCDURNA Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. It is available from one supplier. There are ten… The post New patent expiration for Ferring Pharms drug NOCDURNA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

DECEMBER 28, 2023

Medical billing errors have become a significant issue in the healthcare industry, causing financial losses for hospitals, insurers, and even patients. This article explores the impact of such errors in the United States, with a focus on coding and the need for improved systems and processes.

Hospitals 62

Hospitals 62

Drug Patent Watch

DECEMBER 28, 2023

Annual Drug Patent Expirations for HEPZATO Hepzato is a drug marketed by Delcath Systems Inc and is included in one NDA. It is available from one supplier. There are nine… The post New patent for Delcath Systems drug HEPZATO appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmaceutical Business Review

DECEMBER 28, 2023

In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such therapies in the clinical and preclinical stages of development. The lead programmes of the company, PNT2002 and PNT20031, are presently in the late phase of development.

59

59

pharmacy mentor

DECEMBER 28, 2023

The Omnichannel Approach In an age where pharmacies are rapidly evolving beyond traditional roles, embracing innovative strategies to stand out and succeed is crucial. With the advent of Pharmacy First and the growing trend of private clinics, pharmacies are at a pivotal point. Enter P.R.E.S.C.R.I.B.E.S , a marketing methodology designed to catapult your pharmacy into the forefront of healthcare services.

52

52

pharmaphorum

DECEMBER 28, 2023

Get insights into FH23, the first Digital Medicine & DTx Global Policy Summit, where experts come together to discuss the latest advancements and policies in the digital health and DTx industry. Explore the intersection of technology, medicine, and policy in this global event.

52

52

Pharmaceutical Commerce

DECEMBER 28, 2023

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

52

52

Big Molecule Watch

DECEMBER 28, 2023

On December 19, a German court invalidated CureVac’s messenger RNA technology patent, EP 1 857 122 B1, in a lawsuit brought by CureVac against its rival BioNTech. CureVac, a biopharmaceutical company developing messenger RNA therapeutics for COVID-19 vaccines, announced that it will appeal the decision before the German Federal Court of Justice. This ruling represents the first decision on validity in the ongoing patent litigation between CureVac and BioNTech in Germany.

Vaccines 62

Vaccines 62

Pharmaceutical Technology

DECEMBER 28, 2023

Elpiscience Biopharma has signed an agreement with Astellas Pharma for two new bispecific macrophage engagers for cancer.

52

52

PharmaTech

DECEMBER 28, 2023

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.

52

52

PharmExec

DECEMBER 28, 2023

As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023.

52

52

PharmaTech

DECEMBER 28, 2023

Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?

52

52

Pharma and Life Sciences Blog

DECEMBER 28, 2023

GEP is a leading global provider of AI-powered consulting, outsourcing and technology solutions to procurement and supply chain organizations at Fortune 500 and Global 2000 enterprises worldwide.

40

40

Pharmacy Times

DECEMBER 28, 2023

From newsworthy moments to groundbreaking research, these were the most listened-to podcasts on Pharmacy Focus in 2023.

29

29

Drug Patent Watch

DECEMBER 28, 2023

This chart shows the drugs with the most patents in Costa Rica. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical drugs have the most drug patents in Costa Rica? appeared first on DrugPatentWatch - Make Better Decisions.

45

45

Pharmacy Times

DECEMBER 28, 2023

From newsworthy moments to groundbreaking research, these were the most-read coronavirus-related articles on Pharmacy Times in 2023.

26

26

STAT

DECEMBER 28, 2023

In recent months, evidence suggests, the war in  Ukraine  and the ongoing conflict in  Gaza have led to spikes of multidrug-resistant bacterial infections. This is to be expected; conflicts often create conditions that are perfect for drug resistance to emerge and spread, with the first evidence of this dating back as far as the 1940s.

342

342

Pharmacy Times

DECEMBER 28, 2023

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

26

26

Big Molecule Watch

DECEMBER 28, 2023

According to PWC , “2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels.” Below is a recap of the top M&A deals in 2023 that focus on biologics and biosimilars and were covered on the Big Molecule Watch. Coya Announces Agreement with Dr. Reddy’s Laboratories for Treatment of Neurodegenerative Diseases In March, Coya Therapeutics, Inc.

Biosimilars 67

Biosimilars Labelling 67